Journal of Skin Cancer最新文献_第7页

Current Data on Risk Factor Estimates Does Not Explain the Difference in Rates of Melanoma between Hispanics and Non-Hispanic Whites. 目前的风险因素估计数据并不能解释西班牙裔和非西班牙白人黑色素瘤发病率的差异。

IF 1.1

Journal of Skin Cancer Pub Date : 2016-01-01 Epub Date: 2016-03-22 DOI: 10.1155/2016/2105250

Sonia Kamath, Kimberly A Miller, Myles G Cockburn

{"title":"Current Data on Risk Factor Estimates Does Not Explain the Difference in Rates of Melanoma between Hispanics and Non-Hispanic Whites.","authors":"Sonia Kamath, Kimberly A Miller, Myles G Cockburn","doi":"10.1155/2016/2105250","DOIUrl":"10.1155/2016/2105250","url":null,"abstract":"United States Hispanics have seven times lower melanoma incidence rates than non-Hispanic whites (NHW). It is unclear whether this difference can be explained solely by phenotypic risk factors, like darker skin, or whether modifiable risk factors, like sun exposure, also play a role. The purpose of this paper is to summarize what is currently known about melanoma risk factors among Hispanics and NHWs, and whether or not those differences could explain the difference in melanoma incidence. Through literature review, relative risks and prevalence of melanoma risk factors in Hispanics and NHWs were identified and used to calculate the expected rate in Hispanics and rate ratio compared to NHWs. We found that melanoma risk factors either have similar frequency in Hispanics and NHWs (e.g., many large nevi) or are less frequent in Hispanics but do not explain a high proportion of disease variation (e.g., red hair). Considering current knowledge of risk factor prevalence, we found that melanoma incidence rates in the two groups should actually be similar. Sun exposure behavior among Hispanics may contribute to the explanation for the 7-fold difference in melanoma rates. Currently, limited data exist on sun exposure behavior among Hispanics, but possibilities for improving primary prevention by further studying these practices are substantial. ","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2016 ","pages":"2105250"},"PeriodicalIF":1.1,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10188773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reporting Melanoma: A Nationwide Surveillance of State Cancer Registries 报告黑色素瘤:国家癌症登记的全国监测

IF 1.1

Journal of Skin Cancer Pub Date : 2015-12-29 DOI: 10.1155/2015/904393

Kehinde Raji, Lauren Payne, Suephy C. Chen

{"title":"Reporting Melanoma: A Nationwide Surveillance of State Cancer Registries","authors":"Kehinde Raji, Lauren Payne, Suephy C. Chen","doi":"10.1155/2015/904393","DOIUrl":"https://doi.org/10.1155/2015/904393","url":null,"abstract":"The goal of our study was to determine current melanoma reporting methods available to dermatologists and dermatopathologists and quantify changes in reporting methods from 2012 to 2014. A cross-sectional study design was utilized consisting of website perusal of reporting procedures, followed up by telephone and email inquiry of reporting methods from every state cancer registry. This study was conducted over a six-month period from February to August 2014. A previous similar survey was conducted in 2012 over the same time frame and results were compared. Kansas state cancer registry provided no data. As of August 2014, 96% of 49 state cancer registries had electronic methods available to all designated reporters. Seven (14%) states required an electronic-only method of reporting melanoma cases. Eighty-six percent allowed hard copy pathology report submission. Compared to the 2012 survey, 2 additional states were found to have initiated electronic reporting methods by 2014. In conclusion, a variety of methods exist for reporting diagnosed melanoma cases. Although most state cancer registries were equipped for electronic transmission of cases for mandated reporters, a number of states were ill-equipped for electronic submission from outpatient dermatologists. There was a general trend towards electronic versus nonelectronic reporting from 2012 to 2014.","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"301 4 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2015-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90706734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Diet and Skin Cancer: The Potential Role of Dietary Antioxidants in Nonmelanoma Skin Cancer Prevention 饮食与皮肤癌:饮食抗氧化剂在预防非黑色素瘤皮肤癌中的潜在作用

IF 1.1

Journal of Skin Cancer Pub Date : 2015-10-25 DOI: 10.1155/2015/893149

R. Katta, Danielle N Brown

引用次数: 37

Dual S-100-AE1/3 Immunohistochemistry to Detect Perineural Invasion in Nonmelanoma Skin Cancers. 双S-100-AE1/3免疫组化检测非黑色素瘤皮肤癌的神经周围浸润。

IF 1.1

Journal of Skin Cancer Pub Date : 2015-01-01 Epub Date: 2015-01-18 DOI: 10.1155/2015/620235

Alma C Berlingeri-Ramos, Claire J Detweiler, Richard F Wagner, Brent C Kelly

{"title":"Dual S-100-AE1/3 Immunohistochemistry to Detect Perineural Invasion in Nonmelanoma Skin Cancers.","authors":"Alma C Berlingeri-Ramos, Claire J Detweiler, Richard F Wagner, Brent C Kelly","doi":"10.1155/2015/620235","DOIUrl":"https://doi.org/10.1155/2015/620235","url":null,"abstract":"Background. Perineural invasion (PNI) is an adverse prognostic histologic finding and increases the risk of local recurrence and metastasis. Objective. We aimed to determine if dual immunohistochemical (IHC) staining with S-100 and AE1/3 would increase the detection of PNI on nonmelanoma skin cancers (NMSCs). Methods. We collected 45 specimens of NMSCs in which there was clinical suspicion for PNI. Two dermatopathologists independently reviewed the tumors for the unequivocal presence of PNI. Results. Unequivocal PNI was present on 10 of the 45 tumors by H&E staining and on 15 of the 45 tumors by IHC staining. Large nerves (>0.1 mm) were involved in 3 of 10 H&E-stained cases and 3 of 15 IHC-stained cases, with 2 of the 4 cases demonstrating large nerve involvement with both staining methods. Of the 8 cases of PNI detected only on IHC, 7 were small nerves (≤0.1 mm). Limitations. All cases were selected because they were clinically suspicious for PNI, and this may be considered selection bias. Conclusions. PNI detection may be increased using dual S-100 and AE1/3 staining, but the majority of additional cases detected were small nerves. The clinical significance, given the small size of the involved nerves, is unclear. ","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2015 ","pages":"620235"},"PeriodicalIF":1.1,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/620235","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33041995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Reducing Sun Exposure for Prevention of Skin Cancers: Factorial Invariance and Reliability of the Self-Efficacy Scale for Sun Protection. 减少日晒预防皮肤癌:防晒自我效能量表的因子不变性和可靠性。

IF 1.1

Journal of Skin Cancer Pub Date : 2015-01-01 Epub Date: 2015-09-17 DOI: 10.1155/2015/862732

Steven F Babbin, Hui-Qing Yin, Joseph S Rossi, Colleen A Redding, Andrea L Paiva, Wayne F Velicer

{"title":"Reducing Sun Exposure for Prevention of Skin Cancers: Factorial Invariance and Reliability of the Self-Efficacy Scale for Sun Protection.","authors":"Steven F Babbin, Hui-Qing Yin, Joseph S Rossi, Colleen A Redding, Andrea L Paiva, Wayne F Velicer","doi":"10.1155/2015/862732","DOIUrl":"https://doi.org/10.1155/2015/862732","url":null,"abstract":"The Self-Efficacy Scale for Sun Protection consists of two correlated factors with three items each for Sunscreen Use and Avoidance. This study evaluated two crucial psychometric assumptions, factorial invariance and scale reliability, with a sample of adults (N = 1356) participating in a computer-tailored, population-based intervention study. A measure has factorial invariance when the model is the same across subgroups. Three levels of invariance were tested, from least to most restrictive: (1) Configural Invariance (nonzero factor loadings unconstrained); (2) Pattern Identity Invariance (equal factor loadings); and (3) Strong Factorial Invariance (equal factor loadings and measurement errors). Strong Factorial Invariance was a good fit for the model across seven grouping variables: age, education, ethnicity, gender, race, skin tone, and Stage of Change for Sun Protection. Internal consistency coefficient Alpha and factor rho scale reliability, respectively, were .84 and .86 for Sunscreen Use, .68 and .70 for Avoidance, and .78 and .78 for the global (total) scale. The psychometric evidence demonstrates strong empirical support that the scale is consistent, has internal validity, and can be used to assess population-based adult samples. ","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2015 ","pages":"862732"},"PeriodicalIF":1.1,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/862732","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34250150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Comorbidity Assessment in Skin Cancer Patients: A Pilot Study Comparing Medical Interview with a Patient-Reported Questionnaire. 皮肤癌患者的合并症评估:一项比较医学访谈与患者报告问卷的初步研究

IF 1.1

Journal of Skin Cancer Pub Date : 2015-01-01 Epub Date: 2015-06-09 DOI: 10.1155/2015/953479

Erica H Lee, Rajiv I Nijhawan, Kishwer S Nehal, Stephen W Dusza, Amanda Levine, Amanda Hill, Christopher A Barker

{"title":"Comorbidity Assessment in Skin Cancer Patients: A Pilot Study Comparing Medical Interview with a Patient-Reported Questionnaire.","authors":"Erica H Lee, Rajiv I Nijhawan, Kishwer S Nehal, Stephen W Dusza, Amanda Levine, Amanda Hill, Christopher A Barker","doi":"10.1155/2015/953479","DOIUrl":"https://doi.org/10.1155/2015/953479","url":null,"abstract":"Background. Comorbidities are conditions that occur simultaneously but independently of another disorder. Among skin cancer patients, comorbidities are common and may influence management. Objective. We compared comorbidity assessment by traditional medical interview (MI) and by standardized patient-reported questionnaire based on the Adult Comorbidity Evaluation-27 (ACE-27). Methods. Between September 2011 and October 2013, skin cancer patients underwent prospective comorbidity assessment by a Mohs surgeon (MI) and a radiation oncologist (using a standardized patient-reported questionnaire based on the ACE-27, the PRACE-27). Comorbidities were identified and graded according to the ACE-27 and compared for agreement. Results. Forty-four patients were evaluated. MI and PRACE-27 identified comorbidities in 79.5% and 88.6% (p = 0.12) of patients, respectively. Among 27 comorbid ailments, the MI identified 9.9% as being present, while the PRACE-27 identified 12.5%. When there were discordant observations, PRACE-27 was more likely than MI to identify the comorbidity (OR = 5.4, 95% CI = 2.4-14.4, p < 0.001). Overall comorbidity scores were moderate or severe in 43.2% (MI) versus 59.1% (PRACE-27) (p = 0.016). Limitations. Small sample size from a single institution. Conclusion. Comorbidities are common in skin cancer patients, and a standardized questionnaire may better identify and grade them. More accurate comorbidity assessments may help guide skin cancer management. ","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2015 ","pages":"953479"},"PeriodicalIF":1.1,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/953479","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34294397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Mycosis fungoides in Iranian population: an epidemiological and clinicopathological study. 伊朗人群蕈样真菌病:流行病学和临床病理学研究。

IF 1.1

Journal of Skin Cancer Pub Date : 2015-01-01 Epub Date: 2015-01-28 DOI: 10.1155/2015/306543

Farahnaz Fatemi Naeini, Bahareh Abtahi-Naeini, Hamidreza Sadeghiyan, Mohammad Ali Nilforoushzadeh, Jamshid Najafian, Mohsen Pourazizi

{"title":"Mycosis fungoides in Iranian population: an epidemiological and clinicopathological study.","authors":"Farahnaz Fatemi Naeini, Bahareh Abtahi-Naeini, Hamidreza Sadeghiyan, Mohammad Ali Nilforoushzadeh, Jamshid Najafian, Mohsen Pourazizi","doi":"10.1155/2015/306543","DOIUrl":"https://doi.org/10.1155/2015/306543","url":null,"abstract":"Background. Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma. Extensive studies on Iranian MF patients are absent. The present study aimed to produce updated clinical information on Iranian MF patients. Methods. This was a retrospective, descriptive, single-center study, including all cases of MF seen in the Department of Dermatology, University Hospital of Isfahan, Iran, between 2003 and 2013. Data systematically recorded for each patient included clinical, biological, histological, and molecular findings. Results. Eighty-six patients with clinical and histologic diagnosis of MF were included in the study. Thirty-nine patients (45.3%) were male. Female predominance was observed in patients (male : female ratio is 1 : 1.2). Patients were between 7 and 84 years of age (median: 41). The interval from disease onset to diagnosis ranged from 0 to 55 years (median: 1 year). Eighteen cases (20.9%) had unusual variants of MF. The most common types included hypopigmented and poikilodermatous MF. Childhood cases of MF constituted 5.8% (5/86) of all patients. The early stages were seen in 82 cases (95.34%). Conclusion. The major differences in epidemiologic characteristics of MF in Iran are the lack of male predominance and the lower age of patients at the time of diagnosis. ","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2015 ","pages":"306543"},"PeriodicalIF":1.1,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/306543","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33065031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Oculocutaneous Albinism and Squamous Cell Carcinoma of the Skin of the Head and Neck in Sub-Saharan Africa. 撒哈拉以南非洲地区头颈部皮肤白化病和鳞状细胞癌。

IF 1.1

Journal of Skin Cancer Pub Date : 2015-01-01 Epub Date: 2015-08-12 DOI: 10.1155/2015/167847

P T Lekalakala, R A G Khammissa, B Kramer, O A Ayo-Yusuf, J Lemmer, L Feller

引用次数: 50

Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis. 靶向治疗与达卡巴嗪治疗BRAF(V600E)转移性黑色素瘤的比较:成本-效果分析

IF 1.1

Journal of Skin Cancer Pub Date : 2015-01-01 Epub Date: 2015-06-10 DOI: 10.1155/2015/505302

Vanessa Shih, Renske M Ten Ham, Christine T Bui, Dan N Tran, Jie Ting, Leslie Wilson

{"title":"Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis.","authors":"Vanessa Shih, Renske M Ten Ham, Christine T Bui, Dan N Tran, Jie Ting, Leslie Wilson","doi":"10.1155/2015/505302","DOIUrl":"https://doi.org/10.1155/2015/505302","url":null,"abstract":"Purpose. Two BRAF(V600E) targeted therapies, dabrafenib and vemurafenib, have received US approval for treatment of metastatic melanoma in BRAF(V600E) patients, a mutation that affects ~50% of patients. We evaluated the cost-effectiveness of BRAF inhibitors and traditional chemotherapy for treatment of metastatic melanoma. Methods. A Markov model was developed using a societal perspective. Transition probabilities were derived from two Phase III registration trials comparing each BRAF inhibitor against dacarbazine. Costs were obtained from literature, national databases, and Medicare fee schedules. Utilities were obtained from published literature. Deterministic and probabilistic sensitivity analyses were run to test the impact of uncertainties. Results. The incremental cost-effectiveness ratio of dabrafenib was $149,035/QALY compared to dacarbazine. Vemurafenib was dominated by dabrafenib. Probabilistic sensitivity analysis showed that, at a willingness-to-pay (WTP) threshold of ≤$100,000/QALY, dacarbazine was the optimal treatment in ~85% of simulations. At a WTP threshold of ≥$150,000/QALY, dabrafenib was the optimal treatment. Conclusion. Compared with dacarbazine, dabrafenib and vemurafenib were not cost-effective at a willingness-to-pay threshold of $100,000/QALY. Dabrafenib is more efficient compared to vemurafenib. With few treatment options, dabrafenib is an option for qualifying patients if the overall cost of dabrafenib is reduced to $30,000-$31,000 or a WTP threshold of ≥$150,000/QALY is considered. More comparative data is needed. ","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2015 ","pages":"505302"},"PeriodicalIF":1.1,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/505302","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34283005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 22

Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy. 局部晚期和无法切除的皮肤鳞状细胞癌：同时使用西妥昔单抗和放疗的疗效。

IF 1.1

Journal of Skin Cancer Pub Date : 2014-01-01 Epub Date: 2014-07-21 DOI: 10.1155/2014/284582

Robert M Samstein, Alan L Ho, Nancy Y Lee, Christopher A Barker

{"title":"Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy.","authors":"Robert M Samstein, Alan L Ho, Nancy Y Lee, Christopher A Barker","doi":"10.1155/2014/284582","DOIUrl":"10.1155/2014/284582","url":null,"abstract":"Background. Advanced age and immune dysfunction are risk factors for cutaneous squamous cell carcinoma (cSCC) and often render patients with locally-advanced disease medically inoperable or surgically unresectable, but potentially curable with radiotherapy. Concurrent chemotherapy and radiotherapy may not be well tolerated in this population, but another systemic therapy may improve disease control. Objective. Determine the tolerance and efficacy of concurrent cetuximab and radiotherapy (CRT) for patients with locally advanced and unresectable cSCC. Methods. Retrospective analysis of 12 patients treated with CRT for locally advanced and unresectable cSCC. Results. Patients were elderly and 75% had moderate-to-severe comorbidities, while 42% had immune dysfunction. Grades 3-4 adverse events were noted in 83% of patients; 67% required hospital admission for adverse events. Complete and partial response was noted in 36% and 27% (response rate, 64%). Stable and progressive disease was noted in 3 and 1 patients, respectively (disease control rate, 91%). Median progression-free and overall survival were 6.4 and 8.0 months, respectively. Limitations. Retrospective small-cohort, single-institution analysis. Conclusion. Patients selected for CRT were elderly, with comorbidities and immune dysfunction, but treatment responses were observed. Patients selected for this treatment approach have a poor prognosis with limited capacity for therapy; more effective treatment is needed. ","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2014 ","pages":"284582"},"PeriodicalIF":1.1,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32596866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0